Published in Hepatitis Weekly, September 13th, 2004
"The acquisition of CellExSys provides Chromos with a new cell-therapy technology and a strong preclinical pipeline to support product development in the areas of infectious diseases and cancer," said Alistair Duncan, president and CEO of Chromos. "This program accelerates our entry into the clinic, and complements our internal gene-based cell therapy programs, advancing our...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.